MX2022010008A - Composiciones inmunogenicas de coronavirus y usos de las mismas. - Google Patents
Composiciones inmunogenicas de coronavirus y usos de las mismas.Info
- Publication number
- MX2022010008A MX2022010008A MX2022010008A MX2022010008A MX2022010008A MX 2022010008 A MX2022010008 A MX 2022010008A MX 2022010008 A MX2022010008 A MX 2022010008A MX 2022010008 A MX2022010008 A MX 2022010008A MX 2022010008 A MX2022010008 A MX 2022010008A
- Authority
- MX
- Mexico
- Prior art keywords
- immunogenic compositions
- coronavirus
- coronavirus immunogenic
- cov
- sars
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 2
- 241000004176 Alphacoronavirus Species 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente divulgación se proporcionan compuestos inmunogénicos, formulaciones farmacéuticas de los mismos y su uso para inducir una respuesta inmunitaria protectora contra la infección por el nuevo coronavirus (SARS-CoV-2) de 2019 y sus variantes en un mamífero.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062977078P | 2020-02-14 | 2020-02-14 | |
US202062992553P | 2020-03-20 | 2020-03-20 | |
US202063005923P | 2020-04-06 | 2020-04-06 | |
US202063016902P | 2020-04-28 | 2020-04-28 | |
US202063050844P | 2020-07-12 | 2020-07-12 | |
US202063069792P | 2020-08-25 | 2020-08-25 | |
US202063088736P | 2020-10-07 | 2020-10-07 | |
US202163140128P | 2021-01-21 | 2021-01-21 | |
US202163142077P | 2021-01-27 | 2021-01-27 | |
US202163148374P | 2021-02-11 | 2021-02-11 | |
PCT/US2021/017920 WO2021163536A2 (en) | 2020-02-14 | 2021-02-12 | Coronavirus immunogenic compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010008A true MX2022010008A (es) | 2022-11-14 |
Family
ID=77295207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010008A MX2022010008A (es) | 2020-02-14 | 2021-02-12 | Composiciones inmunogenicas de coronavirus y usos de las mismas. |
Country Status (12)
Country | Link |
---|---|
US (2) | US20210260180A1 (es) |
EP (1) | EP4103210A4 (es) |
JP (1) | JP2023514249A (es) |
KR (1) | KR20220154121A (es) |
CN (1) | CN114096675A (es) |
AU (1) | AU2021220971A1 (es) |
BR (1) | BR112022016054A2 (es) |
CA (1) | CA3167833A1 (es) |
IL (1) | IL295548A (es) |
MX (1) | MX2022010008A (es) |
TW (1) | TW202144383A (es) |
WO (1) | WO2021163536A2 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
CN113336832B (zh) * | 2020-03-02 | 2023-04-18 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的蛋白以及含有该蛋白的疫苗 |
AU2021241355A1 (en) | 2020-03-23 | 2022-10-13 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
WO2022013609A1 (en) * | 2020-07-13 | 2022-01-20 | Immunovaccine Technologies, Inc. | Sars-cov-2 vaccine compositions and methods of preparation and use |
BR112022003611A2 (pt) * | 2020-08-22 | 2022-07-26 | Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte | Agente farmacêutico para induzir imunidade específica contra sars-cov-2 |
US20220193225A1 (en) * | 2020-08-31 | 2022-06-23 | Bruce Lyday | Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins |
MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
CN113150085B (zh) * | 2021-04-27 | 2023-04-18 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2感染的组合物 |
CN114560917A (zh) * | 2021-05-18 | 2022-05-31 | 深圳市因诺转化医学研究院 | SARS-CoV-2编码蛋白来源的T细胞表位多肽TFKVSIWNL及其应用 |
WO2022251216A1 (en) * | 2021-05-24 | 2022-12-01 | Epivax, Inc. | T cell epitopes and related compositions useful in the prevention, diagnosis, and treatment of beta-coronaviruses |
EP4144751A1 (en) * | 2021-09-01 | 2023-03-08 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | New coronavirus vaccine and method for designing and obtaining a virus vaccine |
WO2023036814A1 (en) * | 2021-09-07 | 2023-03-16 | Universite De Tours | Coronavirus fusion protein |
CN113957097B (zh) * | 2021-09-27 | 2023-11-28 | 中国食品药品检定研究院 | 一种对新冠变异株广谱中和保护的免疫原及其制备方法和应用 |
WO2023070029A1 (en) * | 2021-10-20 | 2023-04-27 | Arizona Board Of Regents On Behalf Of Arizona State University | DNA ORIGAMI SUBUNIT VACCINE FOR PREVENTION OF SARS-CoV-2 VARIANT INFECTION |
CN116350770A (zh) * | 2021-12-28 | 2023-06-30 | 成都迈科康生物科技有限公司 | 一种带状疱疹疫苗制剂及其制备方法 |
RU2765729C1 (ru) * | 2021-12-29 | 2022-02-02 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Иммунобиологическое средство для индукции иммунного ответа против SARS-CoV-2 и способ его применения (варианты) |
WO2023130096A2 (en) * | 2021-12-31 | 2023-07-06 | Boost Biopharma, Inc. | Coronavirus vaccine compositions and uses thereof |
CN114478717B (zh) * | 2022-01-21 | 2022-10-28 | 国药中生生物技术研究院有限公司 | 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用 |
WO2023150638A2 (en) * | 2022-02-02 | 2023-08-10 | Washington University | Omicron coronavirus vaccine constructs and methods of making and using same |
CN116726162A (zh) * | 2022-03-11 | 2023-09-12 | 病毒与疫苗研究中心有限公司 | 用于呼吸道病毒性疾病的疫苗加强组合物 |
CN114702556A (zh) * | 2022-03-22 | 2022-07-05 | 中国人民解放军军事科学院军事医学研究院 | 一种冠状病毒rbd变异体及其应用 |
CN114717205A (zh) * | 2022-03-29 | 2022-07-08 | 中国人民解放军军事科学院军事医学研究院 | 一种冠状病毒RBDdm变异体及其应用 |
CN114574502B (zh) * | 2022-04-11 | 2023-07-14 | 四川大学 | 一种以复制缺陷腺相关病毒为载体的新型冠状病毒疫苗 |
WO2023200858A1 (en) * | 2022-04-13 | 2023-10-19 | The Trustees Of Columbia University In The City Of New York | Inhibitory peptides against coronaviruses |
CN114934056B (zh) * | 2022-06-24 | 2023-10-20 | 仁景(苏州)生物科技有限公司 | 一种基于新型冠状病毒奥密克戎突变株的mRNA疫苗 |
TWI833281B (zh) * | 2022-07-08 | 2024-02-21 | 國防醫學院 | 用於增加基因表現之冠狀病毒核殼蛋白片段及其應用 |
CN115287265B (zh) * | 2022-07-12 | 2023-05-23 | 四川大学华西医院 | 多能活性制剂诱发恒河猴抵抗新冠突变体的免疫防治模型 |
WO2024026553A1 (en) * | 2022-08-03 | 2024-02-08 | Centre Hospitalier De L'université De Montréal | Novel antigenic epitope against sars-cov-2 and uses thereof |
WO2024050451A2 (en) * | 2022-08-31 | 2024-03-07 | Think Therapeutics, Inc. | Compositions and methods for optimized covid peptide vaccines |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200100936T2 (tr) * | 1998-10-05 | 2001-08-21 | Pharmexa A/S | Terapötik aşılama |
KR20220047790A (ko) * | 2011-03-21 | 2022-04-19 | 알티뮨 인크. | 급속 및 지속적 면역학적제제-치료제 |
CA3200425A1 (en) * | 2012-11-16 | 2014-05-22 | Peter ABBINK | Recombinant adenoviruses and use thereof |
GB201708444D0 (en) * | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
WO2021155323A1 (en) * | 2020-01-31 | 2021-08-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines |
US20240123053A1 (en) * | 2020-05-07 | 2024-04-18 | Bharat Biotech International Limited | Coronavirus vaccine through nasal immunization |
-
2021
- 2021-02-12 BR BR112022016054A patent/BR112022016054A2/pt not_active Application Discontinuation
- 2021-02-12 IL IL295548A patent/IL295548A/en unknown
- 2021-02-12 US US17/175,131 patent/US20210260180A1/en not_active Abandoned
- 2021-02-12 KR KR1020227031741A patent/KR20220154121A/ko unknown
- 2021-02-12 JP JP2022548966A patent/JP2023514249A/ja active Pending
- 2021-02-12 AU AU2021220971A patent/AU2021220971A1/en active Pending
- 2021-02-12 EP EP21754079.8A patent/EP4103210A4/en active Pending
- 2021-02-12 MX MX2022010008A patent/MX2022010008A/es unknown
- 2021-02-12 CA CA3167833A patent/CA3167833A1/en active Pending
- 2021-02-12 WO PCT/US2021/017920 patent/WO2021163536A2/en unknown
- 2021-02-12 CN CN202180001745.8A patent/CN114096675A/zh active Pending
- 2021-02-17 TW TW110105306A patent/TW202144383A/zh unknown
- 2021-06-09 US US17/342,769 patent/US11382968B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11382968B2 (en) | 2022-07-12 |
IL295548A (en) | 2022-10-01 |
KR20220154121A (ko) | 2022-11-21 |
BR112022016054A2 (pt) | 2022-10-11 |
US20210260180A1 (en) | 2021-08-26 |
US20220072121A1 (en) | 2022-03-10 |
EP4103210A2 (en) | 2022-12-21 |
AU2021220971A1 (en) | 2022-10-06 |
CN114096675A (zh) | 2022-02-25 |
EP4103210A4 (en) | 2024-03-20 |
WO2021163536A2 (en) | 2021-08-19 |
WO2021163536A3 (en) | 2021-10-21 |
JP2023514249A (ja) | 2023-04-05 |
TW202144383A (zh) | 2021-12-01 |
CA3167833A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010008A (es) | Composiciones inmunogenicas de coronavirus y usos de las mismas. | |
PT1187629E (pt) | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador | |
MY129263A (en) | Vaccine composition | |
HK1060694A1 (en) | Herbal compositions useful as chemopreventive and therapeutic agents. | |
NO20005051L (no) | Adjuvantsammensetninger | |
BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
MX2007006241A (es) | 2-alcoxi-3,4,5-trihidroxi-alquilamidas, su preparacion, composiciones que las contienen y su utilizacion. | |
GB2386072A (en) | Novel vaccine | |
WO2004043376A3 (en) | Compositions and methods for treating or preventing pneumococcal infection | |
IL157540A0 (en) | N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof | |
CO5540370A2 (es) | Comprimido que comprende cetirizina y pseudoefredina | |
MX2022006940A (es) | Composiciones farmaceuticas. | |
SE0200657D0 (sv) | Novel Formulation | |
DK1476467T3 (da) | IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf | |
PH12020500228A1 (en) | Pharmacutical composition comprising remogliflozin and antidiabetic agent | |
GB0001315D0 (en) | Organic compounds | |
BRPI0414073A (pt) | método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo | |
MX2022004014A (es) | Composicion liofilizada que contiene 2-((s)-2-acetamido-3-(1h-indo l-3-il)propanamido)-6-diazo-5-oxohexanoato de (s)-isopropilo para administracion intravenosa y su uso. | |
ZA202104746B (en) | Novel trypanosomal vaccine | |
AR040764A1 (es) | Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina | |
AR121351A1 (es) | Composiciones inmunogénicas contra coronavirus y usos de las mismas | |
AU2003202550A1 (en) | Pharmaceutical formulations with modified release | |
AR027738A1 (es) | Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas | |
HK1054199A1 (en) | Parenteral vaccine formulations and uses thereof | |
WO2020227605A3 (en) | Dna encoded il-36 gamma as an adjuvant |